IsomAb

Executive Summary

IsomAb is a UK-based biotechnology company pioneering isoform-specific antibody therapeutics for cardiovascular diseases, with a focus on chronic stable angina. Its lead candidate, ISM-001, is designed to neutralize a specific anti-angiogenic VEGF isoform, thereby promoting the growth of collateral blood vessels—a natural ‘biological bypass’ that could alleviate symptoms and improve outcomes for patients with limited treatment options. Founded in 2021 as a spin-out from the University of Nottingham, the company leverages deep expertise in vascular biology and antibody engineering. Despite being in early preclinical development, IsomAb’s differentiated mechanism addresses a critical unmet need in cardiovascular medicine, where current therapies do not restore blood flow adequately. The company is privately held with no disclosed funding rounds, but its novel approach has attracted interest from academic collaborators and potential partners.

Upcoming Catalysts (preview)

• Q3 2026ISM-001 IND/CTA Filing30% success
• Q3 2026Series A Financing or Grant Award50% success
• Q3 2026Publication of Preclinical Proof-of-Concept Data70% success